Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS

Background: Several poly ADP ribose polymerase inhibitors (PARPis) are currently approved for the treatment of a variety of cancers. The safety profile of PARPis has not yet been systemically analyzed in the real world. We conducted this pharmacovigilance analysis using the US FDA’s Adverse Event Re...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Xiaojiang, Chen, Lin, Gai, Di, He, Sijie, Jiang, Xuan, Zhang, Ni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990839/
https://www.ncbi.nlm.nih.gov/pubmed/35401230
http://dx.doi.org/10.3389/fphar.2022.851246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990839/
https://www.ncbi.nlm.nih.gov/pubmed/35401230
http://dx.doi.org/10.3389/fphar.2022.851246

Ejemplares similares